Licensing Agreements

Quest Diagnostics licenses technology for genetic screening for Fragile X Syndrome

Published in Biotech Law Weekly, February 23rd, 2007

In a move that promises to advance physicians' ability to widely screen for Fragile X Syndrome (FXS), the most common form of inherited mental retardation, Quest Diagnostics Incorporated (DGX) announced the signing of a worldwide license agreement with U.S. Genomics.

The terms grant Quest Diagnostics rights to develop an advanced screening method for FXS based on Quest Diagnostics' and U.S. Genomics' jointly developed genetic testing technology. Additional terms of the agreement were not disclosed. Approximately one in 1,500 males and one in 4,000 to 6,000 females worldwide are born with FXS.

Using U.S. Genomics' applications, Quest Diagnostics plans...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2007-02-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry